



Zeal & Innovation in Medicine

Ref : ZLL/ CS/LODR/Compliance/

Date : 28.06.2023

Bombay Stock Exchange Limited Department of Corporate Services, SP. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code-541400)	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol: ZIMLAB)
---	--

Dear Sir/Madam,

Sub: **Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Press Release**

We would like to inform you that the Company has agreed for strategic investments In Australia and MENA region.

Please find enclosed a press release with respect to the same.

Kindly take this intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl. as above.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960



ZIM Lab Invests in Key Partnerships in Australia and MENA

Nagpur, 28th June 2023: ZIM Laboratories Limited (ZIM or the Company) has announced strategic investments in Australia and the MENA region to expand its presence in Developed and Pharmerging markets. For Australia and New Zealand markets, ZIM's Board has approved an investment in a local start-up company to enhance its registration, marketing, distribution, and sales capabilities for New Innovative Products (NIP) and Oral Thin Films (OTF). The investment grants ZIM 99% ownership of the company.

In the MENA region, ZIM's subsidiary, ZIM Laboratories FZE, Sharjah, will invest and partner with a local experienced business entrepreneur, through a step-down majority owned subsidiary, to obtain regulatory approvals and facilitate marketing, distribution, and sales of its various products in specific regional markets. These initiatives signify the company's growth plans and its aim to introduce innovative products for expansion across new markets.

About ZIM Laboratories Limited

ZIM Laboratories Limited is research driven pharmaceutical company focused on providing innovative drug delivery solutions that improve patient convenience and treatment adherence. ZIM acts as a research centric end to end product development partner for its customers across Key Developed, Pharmerging and RoW markets by providing a constant pipeline of therapy agnostic finished and semi-finished pharmaceutical and nutraceutical formulation products.

For more information, please visit the Co's website www.zimlab.in Or contact:

Investor Relations, ZIM Labs – ir@zimlab.in ; +91 9022434631